ADCs

With over ten years of experience supporting antibody drug conjugate (ADC) discovery, development and manufacturing, our multidisciplinary team has worked with a range of different antibodies, linkers and toxins to enable us to develop customised bioconjugation approaches and offer complex ADC solutions to our customers.

All articles

One pager2 min read

Reduced subunit analysis of a PDB based antibody drug conjugate

Subunit analysis of Zynlonta using a SCIEX X500B Mass Spectrometer

Picture of Chris Nortcliffe, Mass Spectrometry Manager at Radiofilum, presenter of "The use of mass spectrometry to aid ADC development" webinar

Webinar13 min read

The use of mass spectrometry to aid ADC development Read more

One pager3 min read

Measurement of ADC free drug after plasma incubation

Antibody drug conjugates (ADCs) combine a monoclonal antibody (mAb) scaffold with a number of cytotoxic drugs.

Article7 min read

ADC Overview Read more

Image taken from antibody drug conjugates ADCs at Radiofilum animation

Animation2 min read

Antibody drug conjugates (ADCs) at Radiofilum Read more

News2 min read

Radiofilum expands ADC capabilities and laboratory capacity at Deeside

Radiofilum Pharmaceutical Solutions today announced a £1 million expansion project at its Deeside, UK site, which is the company’s dedicated bioconjugation and antibody-drug conjugates (ADCs) facility. The project will increase the current laboratory space from 275 to 419 square meters and establish cGMP bioconjugation/ADC manufacturing capabilities.